At Archimed, we work closely with our portfolio company leadership teams to support value creation. As part of this approach, we regularly engage with senior finance leaders to contribute their experience at key moments of growth, transformation, or transition.
We are currently interested in connecting with experienced finance executives who have operated in private equity–backed environments and bring strong exposure to transaction processes, post-acquisition integration, and hands-on financial performance improvement.
Typical areas of contribution may include:
- Deal execution and exit preparation
- M&A integration support
- Financial performance, cash and OPEX improvement initiatives
- Strengthening finance organizations and leadership teams
- Review and challenge of business plans and cash forecasts
Requirements
This opportunity is intended for senior finance leaders with:
- a strong international background (Europe / US),
- prior CFO experience,
- the capacity of (co)leading projects such as restructuring, carve-out
- a solid foundation in audit and transaction services.
This is not a traditional recruitment process, but an opportunity to explore a potential collaboration within Archimed and its portfolio, in a flexible and impact-driven framework.
What We Do
With offices in Europe, North America and APAC, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.
